EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients

BACKGROUND: Graft rejection and chronic CNI toxicity remain obstacles to organ transplant success. Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. As dosing non-compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wöhl, D. S., James, B., Götz, M., Brennfleck, F., Holub-Hayles, I., Mutzbauer, I., Baccar, S., Brunner, S. M., Geissler, E. K., Schlitt, H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176804/
https://www.ncbi.nlm.nih.gov/pubmed/37170284
http://dx.doi.org/10.1186/s13063-023-07344-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176804/
https://www.ncbi.nlm.nih.gov/pubmed/37170284
http://dx.doi.org/10.1186/s13063-023-07344-7

Ejemplares similares